TTP has partnered with Hovione Technology and H&T Presspart to design a new respiratory device; the PowdAir® Plus Dry Powder Inhaler (DPI)

• Bilim Pharmaceuticals has combined PowdAir Plus with its formulation expertise to launch Ventofor Combi Fix, a formulation of Budesonide and Formoterol for asthma and COPD management, in the Turkish market
• The innovative dry powder inhaler is designed to be sustainable, efficient and cost-effective, helping thousands of global asthma and COPD sufferers better access medication at a fraction of the cost
• The inhaler is the latest respiratory technology product that TTP has designed, showing its market-leading medical device design expertise, and following on from other designs such as the Symbicort pMDI counter and the K-Haler, as well as the CoVent ventilator 

TTP plc, a leading independent technology and product development company that invents and develops breakthrough products and technologies, was a key partner to Hovione Technology and H&T Presspart to develop and optimise a ground-breaking new dry powder inhaler designed to be as cost-effective and easy-to-use as possible.

The new PowdAir Plus DPI is robust, multi-use, with a sleek design. The device is based on the technology behind the highly successful TwinCaps device, designed and optimised by TTP and Hovione Technology and marketed in Japan by Daiichi Sankyo as Inavir®.

A particularly useful design feature is the way the new device cuts the capsule as the tray closes. Patients do not need to pierce the capsule as a separate action, so using the inhaler is simpler, increasing compliance and hence efficacy.

The ability to reuse the device across many capsules reduces the waste associated with disposable inhalers and provides freedom for prescription formats; varying the number of capsules provided with a single inhaler.

‍

The beauty of the PowdAir Plus DPI is its incredibly simple design. It’s only got four plastic parts, eliminating the metal blades or pins in other designs, which makes it less expensive to produce. This innovative inhaler will offer greater choice to the millions of patients suffering from chronic respiratory or pulmonary problems, at a fraction of the normal cost. Until now, the range of reusable inhalers on offer has been quite limited. This new design is indicative of TTP’s – and the wider sector’s – growing ability to work together to design innovative, yet simple, technology to help solve some of the world’s most critical health problems – improving access to affordable treatment at a mass population level.
‍
Clennell Collingwood
Digital Health and Medical Devices Consultant at TTP

‍

Currently 5.4 million people in the UK are receiving treatment for asthma with, on average, three people dying from an asthma attack every day.¹ For those with respiratory conditions like asthma, managing the condition comes down to effective and ongoing treatment, often through the use of pressurised metered dose inhalers (pMDI) – or ‘puffers’ – that release a measured dose of drug via a propellant every time the canister is pushed down.

TTP and Hovione Technology specifically worked together to create the PowdAir Plus DPI to be as affordable as possible. In addition, dry powder inhalers – unlike pressurised inhalers – do not release greenhouse gases to the environment and, with the drug being delivered through a dry powder sealed within a capsule, offer an alternative method which delivers medication deep into the lungs.

‍

The recent pandemic has raised awareness globally that we need better, more effective products, that are easier to use and to administer to people. The PowdAir Plus DPI was designed with these patients in mind – we wanted to provide a cost-effective product solution that would work at scale to help millions more asthma and COPD sufferers. We’ve worked closely with TTP for years to develop a number of respiratory products, and have always been impressed by their inventiveness, lateral thinking and ability to deliver. Our partnership has shown the benefits of working together to design innovative and reliable technologies that can be quickly turned into manufacturable products.
‍
Peter Villax
CEO, Hovione Technology

‍

Hovione Technology and TTP have a long history of working in partnership, having designed the TwinCaps inhaler together in response to the bird flu pandemic in 2006. Launched by Daiichi Sankyo, Japan’s second largest pharmaceutical company, TwinCaps outsold Relenza and Tamiflu within the first six months and is the world’s best-selling, disposable inhaler. It is still the best selling anti-viral for influenza in Japan.

TTP has extensive experience developing innovative respiratory products at pace – the firm designed the dose counter for AstraZeneca’s Symbicort® inhaler, creating a more reliable product for patients and reducing the chance of a patient missing a life-saving medicine dose.TTP also contributed to the development of new technologies for the Mundipharma’s K-Haler®, which won two A’ Design Platinum Awards in 2018 for ‘Scientific Instruments, Medical Devices & Research Equipment Devices’ and ‘Ease of Use and Universal Design’. More recently, TTP took a leading role in the Government’s Ventilator Challenge to design a new ventilator in response to Covid-19.

‍

We are pleased to partner with TTP and Hovione Technology on developing the PowdAir Plus device. The development of a respiratory device is challenging and requires the combined expertise of the three parties involved. Respiratory diseases are on the rise globally which demands smart and affordable drug delivery solutions. The launch of PowdAir Plus on the Turkish market with Bilim Pharmaceuticals marks an important step towards providing such solutions to the patients. PowdAir Plus is the perfect DPI device for markets in need of a robust, simple and cost effective design.
‍
Christian Kraetzig
President of H&T Presspart

About TTP’s Drug Delivery & Digital Health Team

At TTP, we transform bold ideas into breakthrough drug delivery solutions, guiding you from a blank sheet to clinical reality. Our interdisciplinary drug delivery product development team partners with you to help you address the toughest challenges, leveraging deep engineering, human factors, and scientific expertise. With over 70 successful drug delivery systems commercially available, ranging from injectables to complex infusion pumps, we excel at developing efficient, scalable devices aligned with market demands. Trusted by nine of the world’s top ten pharmaceutical leaders, we drive projects from early exploration through to manufacturing and launch, ensuring high-impact, low-risk solutions that enable the delivery of transformative therapies and enhanced patient experiences.

‍